Onco Actu du 3 juin 2020

	1. BIOLOGIE
Discovery in human acute myeloid leukemia could provide novel pathway to new treatments [EurekAlert!] In a study published in June in Cell Reports, the team described how they used induced pluripotent stem cells from a patient with AML to recreate leukemia stem cell biology in the lab, revealing that AML leukemia stem cells lose their leukemic properties once the transcription factor is knocked down or deleted. The researchers further showed that AML cells from other patients were RUNX1-dependent.
	4.12 BIOPSIES LIQUIDES
Study Examines Whether Blood Test Can Identify Early Cancers [NCI] Researchers led by Nickolas Papadopoulos, Ph.D., of Johns Hopkins University School of Medicine, designed the study to see whether it was possible to use such a blood test to detect cancers before symptoms developed. They also wanted to make sure the testing process did not cause participants distress or lead to many unnecessary diagnostic procedures.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Tulane scientists find a switch to flip and turn off breast cancer growth and spread [Tulane University] While targeting Rab27a delays progression of tumor growth, it fails to affect the spread of tiny amounts of cancer cells, or micrometastasis. On the contrary, targeting TRAF3IP2 suppresses tumor growth and spread, and interfering with it both shrinks pre-formed tumors and prevents additional spread.
	5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
Researchers Identify Key Immune Checkpoint Protein That Operates Within T Cells [Ohio State University] “Our findings suggest that PCBP1 is a global intracellular immune checkpoint, and that targeting it would offer a way to influence antitumor responses during immune therapy.”
	5.12.6 IMMUNOTHÉRAPIES - AMM
FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer [Roche] Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable or metastatic hepatocellular carcinoma.
	5.2.6 PHARMA - BIOTECH
Hillhouse leads $160M round for Chinese antibody maker Genor [Fierce Biotech] Founded in 2007, Genor is developing antibodies to treat a range of solid tumors and blood cancers as well as autoimmune diseases like rheumatoid arthritis. It counts more than 10 clinical-stage assets, several of which are in pivotal or phase 3 studies.
	5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
European Commission approves Sarclisa® (isatuximab) for adults with relapsed and refractory multiple myeloma [Sanofi] EC approval based on data from first randomized Phase 3 trial (ICARIA-MM) to report results evaluating an anti-CD38 monoclonal antibody combined with pomalidomide and dexamethasone (pom-dex).
EMA Recommends Granting a Marketing Authorisation for Alpelisib [ESMO] Alpelisib is intended for the treatment of advanced breast cancer with a PIK3CA mutation.
	5.4 TRAITEMENTS - ECONOMIE
NIH funded research related to every new cancer drug approved from 2010-2016, totals $64B [EurekAlert!] The new report from the Center for Integration of Science and Industry, published in The Lancet Oncology, shows that the United States government invested $64 billion in research related to these 59 drugs.
	5.5.16 ASCO (MÉDECINE DE PRÉCISION)
Evidence for Targeted Treatment Builds in Cancers of Unknown Primary but Randomized Data Pending [Genome Web] New data presented over the weekend at the American Society of Clinical Oncology's virtual annual meeting, has added to growing evidence that genomic sequencing, in particular liquid biopsy tests, can identify actionable alterations in patients with cancers of unknown primary (CUP).
	5.9.3 EHA
Sarclisa® (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma [Sanofi] Results from first planned interim analysis of the Phase 3 IKEMA trial selected as late-breaking presentation at EHA25 Virtual Congress.
	6.15 LUTTE CONTRE LES CANCERS - COVID-19
Impact of COVID-19 infection in blood cancer patients [Queen Mary University of London] The study, published in the British Journal of Haematology, looked at 35 adult patients with blood cancer who had tested positive for COVID-19 and monitored them for a minimum of 14 days. At the end of the observation period, 60 per cent of patients had recovered from COVID-19 infection.